Celecoxib and Erlotinib in Treating Patients With Liver Cancer

Withdrawn before enrolling · Phase 1/Phase 2

Conditions studied: Liver Cancer

In brief

RATIONALE: Celecoxib and erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for their growth. Celecoxib may also stop the growth of liver cancer by blocking blood flow to the tumor. PURPOSE: This phase I/II trial is studying the side effects and best dose of giving celecoxib together with erlotinib and to see how well they work in treating patients with liver cancer.

Key facts

Study ID

NCT00293436

Run by

University of California, San Francisco

People needed

0

Starts

2005-01-01

Last updated by the study team

2012-09-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• UCSF Comprehensive Cancer Center — San Francisco, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.